Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

The stock price of Vaxart Inc (NASDAQ: VXRT) fell by 3.8%. This is why it happened.

Vaxart Stock Fell 3.8%: Why It Happened

Vaxart Inc (NASDAQ: VXRT) has granted Altesa Biosciences Inc an exclusive worldwide license to develop and commercialize Vaxart's patented formulation of the capsid-binding Vapendavir, a clinical-stage broad-spectrum antiviral. Under the terms of the agreement, Vaxart is eligible to receive up to $130 million in milestone payments and tiered royalties ranging from the low-single to low-double digits on product sales for multiple indications.

Vaxart Inks Antiviral Asset Licensing Pact With Altesa Biosciences

Milestone payments up to $130 million and royalties for global Vapendavir sales

Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset

VXRT stock is known to be a fast mover. Any piece of good news could prove to be a multi-bagger for investors who take an early position.

Vaxart Stock Could Make Another Big Return in the Future

VXRT stock just received a buy recommendation and a $13 price target from Jefferies, based on the promise of a oral vaccine instead of a needle. The post Will the Promise of Avoiding the Needle Pay Off for Vaxart?

Will the Promise of Avoiding the Needle Pay Off for Vaxart?

Coty

Kinross Gold

QUALCOMM

Shift Technologies

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Sizzling Stocks To Buy Now Trading Under $10 With Massive Upside Potential

Today, VXRT stock is climbing higher on an otherwise red day for the markets, as many speculate retail investors could be behind this rise. The post VXRT Stock: Can Redditors Help Vaxart Power Higher?

VXRT Stock: Can Redditors Help Vaxart Power Higher?

Vaxart is still not worth today's price. VXRT stock is worth no more than $6, especially if it's going to need another capital raise.

Vaxart Is Still Not Worth Anywhere Near Its Present Price

Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.

Implied Volatility Surging for Vaxart (VXRT) Stock Options

Dynavax Technologies

Novavax

The declines appear to be caused simply by volatility that's common with small biotech stocks.

Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today

The stock price of Vaxart Inc (NASDAQ: VXRT) increased by 21.9% yesterday. This is why it happened.

VXRT Stock Price: 21.9% Increase Explanation

Stock price plunged in February due to perceived weak antibody responses. Now the company has analogous data showing how immune responses in other areas can overcome the lack of antibody activity.

Vaxart Has A More Sound Reason To Buy Into Its COVID-19 Vaccine Candidate

VXRT stock is on the move as the company received some very bullish coverage from an analyst initiating coverage today. The post VXRT Stock: Why Redditors Are Betting on a Big Squeeze With Vaxart Today appeared first on InvestorPlace.

VXRT Stock: Why Redditors Are Betting on a Big Squeeze With Vaxart Today

Investors are cheering an analyst's positive recommendation.

Why Vaxart Stock Is Skyrocketing Today

GT Biopharma Inc

Novan

Ocugen, Inc.

Are these former penny stocks on your watch list right now? The post 4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now

Smartsheet

Twilio

Zoom Video

PlayAGS

Air Products and Chemicals

Celsius Holdings

Nasdaq

Vertex Pharmaceuticals

With the trading day about halfway over, the markets were sliding lower to close out the week.

Nasdaq, Smartsheet, Twilio, Vaxart, Zoom Video and More Friday Afternoon Analyst Calls

This isn't the first time its coronavirus vaccine pill has disappointed investors.

Why Shares of Vaxart Plummeted 38.6% in May

Reimagining Covid-19 vaccines isn't an easy task, but Vaxart is prepared to innovate - and VXRT stock could move higher at any given moment. The post Bet on a No-Needle Vaccine Strategy with Vaxart appeared first on InvestorPlace.

Bet on a No-Needle Vaccine Strategy with Vaxart

Magnite

Plug Power

Trulieve Cannabis Corp.

Teladoc

If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.

5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street

Inovio Pharmaceuticals

Moderna

Pfizer

These Vaccine Latecomers Could Still Win Big. Here's How

SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its executive officers, Andrei Floroiu, CEO, and Sean Tucker, CSO, are scheduled to present at the SVB Leerink CybeRx Series: Vaccine Forum on Monday, June 21, 2021 at 1:00 p.m. Eastern Time.

Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum

As a company attempting to make oral vaccines, Vaxart has a compelling story. However VXRT stock looks to be many years away from paying off.

Vaxart's Compelling Story Will Take a Long Time to Play Out

Prior to the vaccination rollout from Vaxart's competitors, VXRT stock appeared a compelling alternative. That's no longer the case.

With Fading Covid-19 Infections, Vaxart's Relevance Is Waning

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu, CEO and Sean Tucker, CSO of the Vaxart executive team are scheduled to present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 1:30 p.m. Eastern Time.

Vaxart to Present at the Jefferies Virtual Healthcare Conference

Vaxart's vaccine pill could prove to be effective against the original Covid-19 virus and its new variants, sending VXRT stock sky-high. The post Speculators Should Consider Buying Vaxart Stock appeared first on InvestorPlace.

Speculators Should Consider Buying Vaxart Stock

News for Vaxart Stock (VXRT)